Pooyan Kazemian1,2,3, Deborah J Wexler3,4, Naomi F Fields1, Robert A Parker1,3,5, Amy Zheng3, Rochelle P Walensky1,2,3,6. 1. 1 Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts. 2. 2 Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts. 3. 3 Department of Medicine, Harvard Medical School, Boston, Massachusetts. 4. 4 Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts. 5. 5 Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts. 6. 6 Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
Background: Type 2 diabetes mellitus (T2DM) affects ∼30 million people in the United States and ∼400 million people worldwide, numbers likely to increase due to the rising prevalence of obesity. We sought to design, develop, and validate PREDICT-DM (PRojection and Evaluation of Disease Interventions, Complications, and Treatments-Diabetes Mellitus), a state-transition microsimulation model of T2DM, incorporating recent data. Methods: PREDICT-DM is populated with natural history, risk factor, and outcome data from large-scale cohort studies and randomized clinical trials. The model projects diabetes-relevant outcomes, including cardiovascular and renal disease outcomes, and 5/10-year survival. We assessed the model validity against 62 endpoints from ACCORD (Action to Control Cardiovascular Risk in Diabetes), VADT (Veterans Affairs Diabetes Trial), and Look AHEAD trials via several comparative statistical methods, including mean absolute percentage error (MAPE), Bland-Altman graphs, and Kaplan-Meier curves. Results: For the comparison between simulated and observed outcomes of the intervention/control arms of the trial, the MAPE was 19%/25% (ACCORD), 29%/20% (VADT), and 42%/10% (Look AHEAD). The Bland-Altman's 95% limit of agreement was 0.02 (ACCORD), 0.03 (VADT), and 0.01 (Look AHEAD), and the mean difference (95% confidence interval) for the comparison between PREDICT-DM and trial endpoints was 0.0025 (-0.0018 to 0.0070) for ACCORD, -0.0067 (-0.0137 to 0.0002) for VADT, and -0.0033 (-0.0067 to 0.00002) for Look AHEAD, indicating an adequate model fit to the data. The model-driven Kaplan-Meier curves were similarly close to those previously published. Conclusions: PREDICT-DM can reasonably predict clinical outcomes from ACCORD and other clinical trials of U.S. patients with T2DM. This model may be leveraged to inform clinical strategy questions related to the management and care of T2DM in the United States.
Background: Type 2 diabetes mellitus (T2DM) affects ∼30 million people in the United States and ∼400 million people worldwide, numbers likely to increase due to the rising prevalence of obesity. We sought to design, develop, and validate PREDICT-DM (PRojection and Evaluation of Disease Interventions, Complications, and Treatments-Diabetes Mellitus), a state-transition microsimulation model of T2DM, incorporating recent data. Methods: PREDICT-DM is populated with natural history, risk factor, and outcome data from large-scale cohort studies and randomized clinical trials. The model projects diabetes-relevant outcomes, including cardiovascular and renal disease outcomes, and 5/10-year survival. We assessed the model validity against 62 endpoints from ACCORD (Action to Control Cardiovascular Risk in Diabetes), VADT (Veterans Affairs Diabetes Trial), and Look AHEAD trials via several comparative statistical methods, including mean absolute percentage error (MAPE), Bland-Altman graphs, and Kaplan-Meier curves. Results: For the comparison between simulated and observed outcomes of the intervention/control arms of the trial, the MAPE was 19%/25% (ACCORD), 29%/20% (VADT), and 42%/10% (Look AHEAD). The Bland-Altman's 95% limit of agreement was 0.02 (ACCORD), 0.03 (VADT), and 0.01 (Look AHEAD), and the mean difference (95% confidence interval) for the comparison between PREDICT-DM and trial endpoints was 0.0025 (-0.0018 to 0.0070) for ACCORD, -0.0067 (-0.0137 to 0.0002) for VADT, and -0.0033 (-0.0067 to 0.00002) for Look AHEAD, indicating an adequate model fit to the data. The model-driven Kaplan-Meier curves were similarly close to those previously published. Conclusions: PREDICT-DM can reasonably predict clinical outcomes from ACCORD and other clinical trials of U.S. patients with T2DM. This model may be leveraged to inform clinical strategy questions related to the management and care of T2DM in the United States.
Authors: Richard Kahn; Peter Alperin; David Eddy; Knut Borch-Johnsen; John Buse; Justin Feigelman; Edward Gregg; Rury R Holman; M Sue Kirkman; Michael Stern; Jaakko Tuomilehto; Nick J Wareham Journal: Lancet Date: 2010-03-29 Impact factor: 79.321
Authors: Hertzel C Gerstein; Michael E Miller; Saul Genuth; Faramarz Ismail-Beigi; John B Buse; David C Goff; Jeffrey L Probstfield; William C Cushman; Henry N Ginsberg; J Thomas Bigger; Richard H Grimm; Robert P Byington; Yves D Rosenberg; William T Friedewald Journal: N Engl J Med Date: 2011-03-03 Impact factor: 91.245
Authors: Rena R Wing; Paula Bolin; Frederick L Brancati; George A Bray; Jeanne M Clark; Mace Coday; Richard S Crow; Jeffrey M Curtis; Caitlin M Egan; Mark A Espeland; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Barbara Harrison; Helen P Hazuda; James O Hill; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Maria G Montez; Anne Murillo; David M Nathan; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David Reboussin; Judith G Regensteiner; Amy D Rickman; Donna H Ryan; Monika Safford; Thomas A Wadden; Lynne E Wagenknecht; Delia S West; David F Williamson; Susan Z Yanovski Journal: N Engl J Med Date: 2013-06-24 Impact factor: 91.245
Authors: Clyde W Yancy; Margarita Lopatin; Lynne Warner Stevenson; Teresa De Marco; Gregg C Fonarow Journal: J Am Coll Cardiol Date: 2005-12-15 Impact factor: 24.094
Authors: Prabhat Jha; Chinthanie Ramasundarahettige; Victoria Landsman; Brian Rostron; Michael Thun; Robert N Anderson; Tim McAfee; Richard Peto Journal: N Engl J Med Date: 2013-01-24 Impact factor: 91.245
Authors: Andrew J Palmer; Lei Si; Michelle Tew; Xinyang Hua; Michael S Willis; Christian Asseburg; Phil McEwan; José Leal; Alastair Gray; Volker Foos; Mark Lamotte; Talitha Feenstra; Patrick J O'Connor; Michael Brandle; Harry J Smolen; James C Gahn; William J Valentine; Richard F Pollock; Penny Breeze; Alan Brennan; Daniel Pollard; Wen Ye; William H Herman; Deanna J Isaman; Shihchen Kuo; Neda Laiteerapong; An Tran-Duy; Philip M Clarke Journal: Value Health Date: 2018-04-09 Impact factor: 5.725
Authors: Emily P Hyle; Julia H A Foote; Fatma M Shebl; Yiqi Qian; Krishna P Reddy; Shibani S Mukerji; Nattanicha Wattananimitgul; Anand Viswanathan; Lee H Schwamm; Ankur Pandya; Kenneth A Freedberg Journal: BMJ Open Date: 2022-07-06 Impact factor: 3.006
Authors: Krishna P Reddy; Alexander J B Bulteel; Douglas E Levy; Pamela Torola; Emily P Hyle; Taige Hou; Benjamin Osher; Liyang Yu; Fatma M Shebl; A David Paltiel; Kenneth A Freedberg; Milton C Weinstein; Nancy A Rigotti; Rochelle P Walensky Journal: BMJ Open Date: 2020-05-12 Impact factor: 2.692